Surge in Investments Driving Genetic and Pharma Innovations in 2026

Global VC investment in biotech and pharma surged 70.9% quarter-over-quarter in Q3 2025, reaching $5B, signaling strong momentum into 20261.

Genentech more than doubled its investment to $2B in a Holly Springs biomanufacturing facility for next-generation metabolic treatments, part of Roche's $50B U.S. commitment2.

Biopharma industry committed over $480B to U.S. manufacturing and R&D projects as of late 2025, driven by reshoring efforts3.

Novartis's $12B acquisition of Avidity Biosciences, focused on rare muscle disorder therapies, expected to close in 20261.

Roche's $50B U.S. expansion includes new facilities for gene therapy and weight-loss medicines12.

Pharma 5.0 market, encompassing personalized medicine and AI-driven therapies, projected to grow from $78.31B in 2025 to $98.7B by 20291.

Sources:

1. https://richgroupusa.com/2026-pharma-investments/

2. https://www.gene.com/media/press-releases/15096/2026-01-20/genentech-more-than-doubles-investment-i

3. https://www.genengnews.com/insights/trends-for-2026/seven-biopharma-trends-to-watch-in-2026/